Compare · ACON vs NTRA
ACON vs NTRA
Side-by-side comparison of Aclarion Inc. (ACON) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACON and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $58.35B, about 10364.1x ACON ($5.6M).
- NTRA has been more active in the news (10 items in the past 4 weeks vs 3 for ACON).
- NTRA has more recent analyst coverage (25 ratings vs 0 for ACON).
- Company
- Aclarion Inc.
- Natera Inc.
- Price
- -
- -
- Market cap
- $5.6M
- $58.35B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2015
- News (4w)
- 3
- 10
- Recent ratings
- 0
- 25
Aclarion Inc.
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest ACON
- Aclarion to Present at the 20th Annual LD Micro Main Event
- Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
- Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
- Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
- Director Williams Amanda M bought $15,990 worth of shares (5,857 units at $2.73), increasing direct ownership by 29% to 25,857 units (SEC Form 4)
- CFO Gould Gregory A bought $24,500 worth of shares (10,000 units at $2.45), increasing direct ownership by 20% to 60,000 units (SEC Form 4)
- Chief Executive Officer Ness Brent bought $12,091 worth of shares (5,234 units at $2.31), increasing direct ownership by 5% to 111,534 units (SEC Form 4)
- Director Bond Ryan bought $50,059 worth of shares (21,122 units at $2.37), increasing direct ownership by 38% to 76,122 units (SEC Form 4)
- Director Wesemann William bought $5,031 worth of shares (2,150 units at $2.34), increasing direct ownership by 10% to 23,713 units (SEC Form 4)
- Director Neal David K bought $18,000 worth of shares (7,500 units at $2.40), increasing direct ownership by 33% to 30,002 units (SEC Form 4)
Latest NTRA
- SEC Form 4 filed by Natera Inc.
- Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- SEC Form 4 filed by Natera Inc.
- FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
- Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
- Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $1,242,645 worth of shares (3,000 units at $414.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 106,914 units (SEC Form 4)
- CEO AND PRESIDENT Chapman Steven Leonard sold $526,144 worth of shares (1,273 units at $413.31) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 96,926 units (SEC Form 4)